Opportunity Overview
- Transforming women’s health by developing novel patented technology from INDIA for the world.
- Experienced team with multi-disciplinary background supported by a renowned global advisory team.
- Uterine Fibroid surgeries are the most common elective surgery in women and has a global opportunity of $ 4 Billion.
- GYIDETM is a scar-less safe, effective and uterus-preserving technology to treat symptomatic uterine fibroids.
- GYIDETM (GEN1) technology has already been established the technology with obtaining manufacturing license from CDSCO (Indian Regulatory) and also received US FDA clearance for FMRA application.
Key Investment Highlights
- Seeking to raise a INR 20 Crores for global regulatory approval for next generation device and kick starting the commercial activities in INDIA.
- Addressable market in India for uterine fibroids and this technology in terms of surgical procedures in 2023 is expected to be about 0.9 million.
- Expected to grow at a rate of 5% CAGR globally and 15% CAGR in INDIA for the next ten years.
- Addressable market size for uterine fibroids surgical procedures is estimated INR 100 Billion in 2023 & is expected to grow at the rate of 15% CAGR.
- The medical device market for uterine fibroids was INR 12 Billion in 2023 and is expected to grow at 17% CAGR for the next ten years.
Key Financials In INR
| 2025-26 | 2026-27 | 2027-28 | 2028-29 | |
|---|---|---|---|---|
| Revenue | 30,60,000 | 1,94,20,000 | 9,31,32,000 | 20,38,40,000 |
| COGS | 12,24,000 | 77,68,000 | 3,72,52,800 | 8,15,36,000 |
| Gross Profit | 18,36,000 | 1,16,52,000 | 5,58,79,200 | 12,23,04,000 |
| Expenses * | 2,88,45,000 | 2,52,08,400 | 3,85,81,640 | 7,71,63,280 |
| EBITDA | (2,70,09,000) | (1,35,56,400) | 1,72,97,560 | 4,51,40,720 |
* R&D Expenses is not considered.